Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors. Convert’s proprietary insights in both the tumor microenvironment and specific biomarkers as well as the chemical design of prodrugs guide the development of these next-generation therapeutics.
Convert Pharmaceuticals, a Belgian biotech company developing anti-cancer therapeutics, announces that Dr Mariola Söhngen joined as CEO, as the company gears up for its first-in-human clinical trials with its lead program....
Convert Pharmaceuticals has been granted a total of EUR 13,6 million in equity and non-dilutive funding by investors Droia Oncology Ventures, Meusinvest and Spinventure, with non-dilutive support by the Walloon region and the European Eurostars program. The funds will be used to prepare and conduct initial clinical studies with Convert’s lead anti-cancer drug, which may bring a novel approach to tackling certain aggressive and resistant tumors....
Un financement total de 13,6 millions d’EUR a été octroyé à Convert Pharmaceuticals en capital par les investisseurs Droia Oncology Ventures, Meusinvest et Spinventure, ainsi qu’en financement non dilutif de la Région wallonne et du programme européen Eurostars. Les fonds seront utilisés pour préparer et mener des études cliniques sur le premier médicament anti-cancéreux de Convert, qui pourrait apporter une approche novatrice pour combattre certaines tumeurs cancéreuses agressives et résistantes aux traitements classiques....